Biogen rebuts consumer complaints over excessive pricing for drug
MLex Summary: Biogen has said it "disagrees" with complaints filed in Italy and Belgium that its pricing of an orphan drug is excessive and in breach of antitrust rules.The statement follows....To view the full article, register now.
Already a subscriber? Click here to view full article